[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-341303-105":59,"doc-detail-341303-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","nanoparticle-mediated-immunotherapy-in-triple-negative-breast-cancer","Nanoparticle-Mediated Immunotherapy in Triple-Negative Breast Cancer","","Triple-negative breast cancer (TNBC) is a highly aggressive subtype with the poorest prognosis and highest recurrence rates. Limited endocrine and HER2 targets confine standard care largely to chemotherapy, yet long-term use is constrained by toxicity and limited response rates, alongside challenges in drug solubility and delivery. Immunotherapy offers alternatives through immunogenic cell death, immune checkpoint therapy, and immune adjuvant approaches. Nanotechnology enables improved delivery, targeted release, enhanced bioavailability, and synergistic combination regimens using multifunctional nanoparticles. ",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/nanoparticle-mediated-immunotherapy-in-triple-negative-breast-cancer/341303/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/nanoparticle-mediated-immunotherapy-in-triple-negative-breast-cancer/341303.png","ImageObject",300,407,{"name":92,"@type":93},"Maeve","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":19},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is TNBC difficult to treat with conventional targeted therapies?","Question",{"text":112,"@type":113},"TNBC lacks estrogen receptor, progesterone receptor, and HER2, leaving few effective therapeutic targets beyond surgery, radiotherapy, and chemotherapy.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What immunotherapy strategies are highlighted as promising for TNBC?",{"text":117,"@type":113},"The review emphasizes immunogenic cell death, immune checkpoint therapy, and immune adjuvant therapy as promising therapeutic strategies.",{"name":119,"@type":110,"acceptedAnswer":120},"How do nanoparticles improve immunotherapy outcomes in TNBC?",{"text":121,"@type":113},"Nanotechnology can enhance delivery, enable targeted release and improved bioavailability, and support synergistic combination therapies through multifunctional nanoparticle platforms.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},341303,1790461044,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":19,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},5909877438554,"https://ap-avatar.wpscdn.com/avatar/5600025385ad2bf12a7?_k=1778553567797529272","This article is licensed under CC-BY-NC-ND 4.0  \n[pubs.acs.org/journal/abseba](pubs.acs.org/journal/abseba)  Review   \nNanoparticle-Mediated Immunotherapy in Triple-Negative Breast Cancer  \nRuoyi Wang, Xu Huang, Xiaoxi Chen, and Yingchao Zhang *  \n Cite This: ACS Biomater. Sci. Eng. 2024, 10, 3568−3598  \nRead Online  \n\n|  |  |  |  |\n| --- | --- | --- | --- |\n| ACCESS   | Metrics & More |  |  Article Recommendations |\n\nABSTRACT: Triple-negative breast cancer (TNBC) is an aggressive subtype with the worst prognosis and highest recurrence rates. The treatment choices are limited due to the scarcity of endocrine and HER2 targets, except for chemotherapy. However, the side effects of chemotherapy restrict its long-term usage. Immunotherapy shows potential as a promising therapeutic strategy, such as inducing immunogenic cell death, immune checkpoint therapy, and immune adjuvant therapy. Nanotechnology offers unique advantages in the field of immunotherapy, such as improved delivery and targeted release of immunotherapeutic agents and enhanced bioavailability of immunomodulators. As well as the potential for combination therapy synergistically enhanced by nanocarriers. Nanoparticles-based combined application of multiple immunotherapies is designed to take the tactics of enhancing immunogenicity and reversing immunosuppression. Moreover, the increasing abundance of biomedical materials holds more promise for the development of this field. This review summarizes the advances in the field of nanoparticle-mediated immunotherapy in terms of both immune strategies for treatment and the development of biomaterials and presents challenges and hopes for the future.  \nKEYWORDS: immunotherapy, triple-negative breast cancer, immune checkpoint blockage, immunogenic cell death, nanoparticles  \n1. INTRODUCTION  \nBreast cancer is the most common cancer among women globally and is responsible for the second-highest number of cancer-related deaths.1 Triple-negative breast cancer (TNBC), comprising 15−20% of all breast cancers, is characterized by a higher rate of metastasis, recurrence, and death than any other subtypes, resulting in low overall survival rates.2−5 TNBC lacks estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2).6−8 Consequently, there is a lack ofpotential targets for therapeutic interventions. Aside from surgery and radiotherapy, conventional chemotherapy remains the frequently used treatment option for TNBC to eliminate tumors and inhibit metastatic spread.9−11 However, as the commonly available method of systemic treatment, intravenous chemotherapy drugs lead to the widespread dissemination of cancer cells throughout the body and result in drug toxicity. As therapeutic medications that target noncancerous cells and tumor locations often fail to deliver adequate dosages, treatment results may be unfavorable.5, 12 Furthermore, current therapies are limited by drug solubility and absorption in cancerous areas. More precisely, the rate at which standard chemotherapy produces a positive response is only 20%.13 Hence, chemotherapy may assist but does not satisfactorily enhance survival.14 Therefore, creating innovative remedies for individuals who  \ncannot derive advantages from traditional treatments is imperative.  \nNanoparticle-based approaches are currently a prominent field of scientific investigation and represent the most extensively studied domain in drug delivery.15 Nanotechnology offers unique advantages in the field of immunotherapy, such as improved delivery and targeted release of immunotherapeutic agents and enhanced bioavailability of immunomodulators. And the potential of combination therapies that can be synergistically enhanced by nanocarriers. Many of these particles act as amultifunctional drug delivery platform due to their ability to target delivery of tumor antigens and adjuvants, enhance immune activation, augment the efficacy of cell therapies, accommodate multiple therap","cbCaicu0LOr5xV6Y","https://ap.wps.com/l/cbCaicu0LOr5xV6Y","pdf",4876564,31,"English","# INTRODUCTION\n## Breast cancer and TNBC challenges\n## Limits of conventional chemotherapy\n## Rationale for nanoparticle-mediated immunotherapy","[{\"question\":\"Why is TNBC difficult to treat with conventional targeted therapies?\",\"answer\":\"TNBC lacks estrogen receptor, progesterone receptor, and HER2, leaving few effective therapeutic targets beyond surgery, radiotherapy, and chemotherapy.\"},{\"question\":\"What immunotherapy strategies are highlighted as promising for TNBC?\",\"answer\":\"The review emphasizes immunogenic cell death, immune checkpoint therapy, and immune adjuvant therapy as promising therapeutic strategies.\"},{\"question\":\"How do nanoparticles improve immunotherapy outcomes in TNBC?\",\"answer\":\"Nanotechnology can enhance delivery, enable targeted release and improved bioavailability, and support synergistic combination therapies through multifunctional nanoparticle platforms.\"}]","Nanoparticle-Mediated Immunotherapy in Triple-Negative Breast Cancer | PDF",1790041444,78,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a65795d4d169e14a941f0e487e4a8075.webp",983,1296,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d07b5b8c63fc4184d43e60869949db87.webp",982,1295,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1bcee8fcff73d06441f8d1d451bb3125.webp",981,1293,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f03d0130e0c4bf7d4aa9886b47e22800.webp",980,1292]